Halozyme Therapeutics (GB:0J2O)

Halozyme (0J2O) Financial Statements


Halozyme Financial Overview

Halozyme's market cap is currently ―. The company's EPS TTM is $; its P/E ratio is ―; Halozyme is scheduled to report earnings on November 7, 2023, and the estimated EPS forecast is $0.74. See an overview of income statement, balance sheet, and cash flow financials.
Jun 23Mar 23Dec 22Sep 22Jun 22
Income Statement-
Total Revenue$ 221.04M$ 162.14M$ 181.50M$ 208.98M$ 152.37M
Gross Profit$ 170.97M$ 126.97M$ 139.38M$ 161.66M$ 118.42M
EBIT$ 97.65M$ 56.78M$ 75.36M$ 81.22M$ 33.12M
EBITDA$ 118.68M$ 74.62M$ 79.91M$ 110.42M$ 45.66M
Net Income Common Stockholders$ 74.75M$ 39.62M$ 57.70M$ 61.63M$ 22.68M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 348.27M$ 275.61M$ 362.79M$ 265.58M$ 209.36M
Total Assets$ 1.81B$ 1.70B$ 1.84B$ 1.86B$ 1.78B
Total Debt$ 1.50B$ 1.49B$ 1.51B$ 1.50B$ 1.25B
Net Debt$ 1.15B$ 1.22B$ 1.14B$ 1.24B$ 1.04B
Total Liabilities$ 1.66B$ 1.63B$ 1.67B$ 1.77B$ 1.49B
Stockholders Equity$ 151.03M$ 65.85M$ 169.80M$ 96.99M$ 293.17M
Cash Flow-
Free Cash Flow$ 68.47M$ 75.56M$ 90.09M$ 68.63M$ 39.26M
Operating Cash Flow$ 66.85M$ 86.94M$ 82.45M$ 69.64M$ 40.23M
Investing Cash Flow$ 54.99M$ -60.16M$ -1.75M$ -1.01M$ -434.95M
Financing Cash Flow$ 2.45M$ -164.61M$ 6.33M$ -12.40M$ 367.82M
Currency in USD

Halozyme Earnings and Revenue History

Halozyme Debt to Assets

Halozyme Cash Flow

Halozyme Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis